MetaCap

Prime Medicine Inc. Company Profile

NASDAQ: PRMEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.55-0.29 (-7.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Prime Medicine at a glance

Prime Medicine Inc. (NASDAQ: PRME) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Prime Medicine is led by Dr. Allan Reine M.D. and employs about 146 people. The company's shares have traded publicly since 2022.

At a market capitalization of $791.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001894562, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Prime Medicine do?

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Prime Medicine Inc.
Ticker
NASDAQ: PRME
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Allan Reine M.D.
Employees
146
Headquarters
60 First Street, Cambridge, MA, United States
Phone
617 465 0013
IPO year
2022
Market cap
$791.62M
SEC CIK
0001894562
Latest annual report
10-K · Mar 3, 2026

Companies similar to Prime Medicine

PRME peer companies
CompanyPrice% ChgMarket capCompare
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs PRME
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs PRME
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs PRME
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs PRME
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs PRME
IMTXImmatics N.V.5.77-3.03%$878.58Mvs PRME
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs PRME
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs PRME

Related